Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

Clinical trial NCT01129180 · COMPLETED

Trial details

NCT number: NCT01129180
Sponsor: Pierluigi Porcu
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Adult Nasal Type Extranodal NK/T-cell Lymphoma Anaplastic Large Cell Lymphoma Angioimmunoblastic T-cell Lymphoma Hepatosplenic T-cell Lymphoma Peripheral T-cell Lymphoma Post-transplant Lymphoproliferative Disorder Prolymphocytic Leukemia Recurrent Adult T-cell Leukemia/Lymphoma Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma Recurrent Mycosis Fungoides/Sezary Syndrome Small Intestine Lymphoma T-cell Large Granular Lymphocyte Leukemia

Start date: 2010-05-01
Primary completion: 2012-05-01
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.